Teos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid to "maximize" shareholder value.

TIGIT drug collaboration. Company will wind down operations and sell assets, including EOS-984 and EOS-215 programs.

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response.

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...